Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Abstract: A process for the preparation of a compound of general formula (I), wherein R1 is CN or CSNH2; R2 is hydrogen or chloride; and R3 is halogen or haloalkyl or haloalkoxy or SF5 which process comprises reacting a compound of formula (II), where R1, R2 and R3 are as defined above; with a proton source.

Abstract: An analyzer and a method for simultaneously detecting and measuring the concentration of two related analytes, the analytes being substrates for a common enzyme.

Abstract: The present invention relates to a method of determining an individual's predisposition to breast cancer, development of breast cancer, protection against breast cancer and/or responsiveness to therapy for breast cancer. The method comprises the step of determining the androgen receptor genotype at the CAG repeat locus of an individual, or at a locus in linkage disequilibrium with the CAG repeat locus, thereby determining an individual's predisposition to breast cancer, development of breast cancer, protection against breast cancer and/or responsiveness to therapy for breast cancer.

Abstract: A process for the preparation of a compound of the formula (I): wherein R1 is CN or CSNH2; X is N or CR4; R2 and R4 are each independently hydrogen or chloro; R3 is halo, haloalkyl, haloalkoxy or —SF5; R5 and R6 are each independently alkyl and n is 0, 1 or 2; said process comprising reacting a compound of the formula (II): wherein the symbols are as defined above and W is H, with an alkylating agent of the formula (III): R6—Y  (III) wherein R6 is as defined above and Y is a leaving group. The process may also be conducted by reacting a compound of formula (II) initially with an inorganic salt or an organic base, and reacting the resultant salt of the compound of formula (II) with the alkylating agent.

Abstract: A process for the preparation of a compound of general formula (I), wherein R1 is CN or CSNH2; R2 is hydrogen or chloride; and R3 is halogen or haloalkyl or haloalkoxy or SF5 which process comprises reacting a compound of formula (II), where R1, R2 and R3 are as defined above; with a proton source.

Abstract: A process for the preparation of a compound of the formula (I): 1

Abstract: A method and device for detecting myoglobin amongst other mammalian peroxidatively active substances like hemoglobin is disclosed. Since the existing peroxidase-sensitive components do not discriminate between myoglobin and hemoglobin, the present method and device provide discrimination by including a filtration step or component which separates myoglobin from hemoglobin on the basis of their difference in molecular weights. The present method and device offer a quick and easy detection of myoglobin, especially in urine, and may conveniently use existing reagents and apparatus.